Sulfapyridin

Pharmaceuticals -> Metabolite of Sulfasalazine

Pharmaceuticals -> Antibiotics (Sulfonamide)

Pharmaceuticals -> Antibiotics

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

0.9

0.35

less than 1 mg/mL at 72 °F (NTP, 1992)

2.35e-01 g/L

33.1 [ug/mL] (The mean of the results at pH 7.4)

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

376 to 379 °F (NTP, 1992)

192 °C

This chemical does not meet GHS hazard criteria for 12% (6 of 50) of reports.

Danger

H300 (72%): Fatal if swallowed [Danger Acute toxicity, oral]

P203, P260, P261, P264, P270, P272, P273, P280, P301+P316, P302+P352, P308+P316, P318, P321, P330, P333+P317, P362+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 50 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

REACH registered substance: Sulfapyridine (EC: 205-642-7)

Sulfapyridine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

SYMPTOMS: Symptoms of exposure to this compound include fever, rash, agranulocytosis, deposition of crystals in the urinary tract with consequent hematuria or anuria, nausea, vomiting, cyanosis, sensitization and, rarely, granulocytopenia. Other symptoms include acute transient myopia, conjunctivitis, keratitis, disturbances of the optic nerve and retina, temporary impairment of depth perception, swelling of the eyelids, photophobia, lacrimation, Stevens-Johnson syndrome, Lyell syndrome, amblyopia, central scotoma and optic neuritis, usually with papilledema. It can induce crystalluria.

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Sulfapyridine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of <i>p</i>-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

Sulfapyridine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid by means of processing the substrate para-aminobenzoic acid (PABA). Dihydropteroate synthetase activity is vital in the synthesis of folate, and folate is required for cells to make nucleic acids, such as DNA or RNA. So if DNA molecules cannot be built, the cell cannot divide.

Hepatic.

Sulfapyridine has known human metabolites that include Sulfapyridine, N-acetyl.